Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature

Critical Reviews in Oncology/Hematology

Volumn 94, Issue 3, 2015, Pages 360-370

  De Bari, Berardino ^a   Daidone, Antonino ^b   Alongi, Filippo ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF PALERMO   (Italy)

^c SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

Author keywords

Brachytherapy boost; HDR BT; High dose rate brachytherapy; Prostate cancer; Radiobiology; Salvage brachytherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACUTE TOXICITY; ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; NEPHROTOXICITY; PATIENT SAFETY; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RADIATION SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RELIABILITY; REPRODUCTIVE TOXICITY; REVIEW; SALVAGE THERAPY; STEREOTACTIC BODY RADIATION THERAPY; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; ADVERSE EFFECTS; MALE; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION DOSE FRACTIONATION;

BRACHYTHERAPY; DOSE FRACTIONATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84928827585     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.02.003     Document Type: Review

References (58)

1. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W.W., Comber H., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49(6):1374-1403.
2. Smith C.V., Bauer J.J., Connelly R.R., Seay T., Kane C., Foley J., et al. Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. J Urol 2000, 164(6):1964-1967.
3. Peinemann F., Grouven U., Hemkens L.G., Bartel C., Borchers H., Pinkawa M., et al. Low-dose rate brachytherapy for men with localized prostate cancer. Cochrane Database Syst Rev 2011, 7. [CD008871].
4. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996, 14(2 (Feb 1)):449-453.
5. Kotecha R., Yamada Y., Pei X., Kollmeier M.A., Cox B., Cohen G.N., et al. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. Brachytherapy 2013, 128(1):44-49.
6. Salembier C1, Lavagnini P., Nickers P., Mangili P., Rijnders A., Polo A., et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007, 83(1 (Apr)):3-10.
7. Hoskin PJ1, Colombo A., Henry A., Niehoff P., Paulsen Hellebust T., Siebert F.A., et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol 2013, 107(3 (Jun)):325-332.
8. Erickson B.A1, Demanes D.J., Ibbott G.S., Hayes J.K., Hsu I.C., Morris D.E., et al. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2011, 79(3 (Mar 1)):641-649.
9. Aluwini S., Van Rooij P.H., Kirkels W.J., Jansen P.P., Praag J.O., et al. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-Year experience. Int J Radiat Oncol Biol Phys 2012, (Aug 1):83-90.
10. Alongi F., De Bari B., Campostrini F., Arcangeli S., Matei D.V., Lopci E., et al. Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review. Crit Rev Oncol Hematol. 2013, (Dec):88-90.
11. Skowronek J1, Zwierzchowski G., Piotrowski T., Milecki P. Optimization and its influence on value of doses in HDR and PDR brachytherapy. Neoplasma 2010, 57(4):369-376.
12. Skowronek J1, Malicki J., Piotrowski T. Values of biologically equivalent doses in healthy tissues: comparison of PDR and HDR brachytherapy techniques. Brachytherapy 2010, 9(2 (Apr-Jun)):165-170.
13. Martinez A.A., Gustafson G., Gonzalez J., Armour E., Mitchell C., Edmundson G., et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002, (Jun 1):53-60.
14. Pistis F., Guedea F., Pera J., Gutierrez C., Ventura M., Polo A., et al. External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology. Brachytherapy 2010, 9(1 (Mar)):15-22.
15. Joiner M.C., Kogel A., van der. Basic clinical radiobiology 2009, 392. CRC Press. 4th ed.
16. Cosset J.-M., Mornex F., Eschwège F. Hypofractionnement en radiothérapie: l'éternel retour. Cancer Radiother 2013, 17(5-6):355-362.
17. Brenner D.J., Martinez A.A., Edmundson G.K., Mitchell C., Thames H.D., Armour E.P. Direct evidence that prostate tumors show high sensitivity to fractionation [low α/β value], similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52(1 (Jan 1)):6-13.
18. Miralbell R., Roberts S.A., Zubizarreta E., Hendry J.H. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β=1.4 [0.9-2.2]Gy. Int J Radiat Oncol Biol Phys 2012, 82(1 (Jan 1)):e17-e24.
19. Proust-Lima C., Taylor J.M.G., Sécher S., Sandler H., Kestin L., Pickles T., et al. Confirmation of a low α/β value for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 2011, 79(1 (Jan 1)):195-201.
20. Kal H.B1, Van Gellekom M.P. How low is the α/β ratio for prostate cancer?. Int J Radiat Oncol Biol Phys 2003, 57(4 (Nov 15)):1116-1121.
21. Daşu A. Is the α/β value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol (R Coll Radiol) 2007, 19(5 (Jun)):289-301.
22. De Bari B., Fiorentino A., Greto D. Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the young radiation oncologist meeting. Prostate cancer as a paradigm of multidisciplinary approach?. Highlights from the young radiation oncologist meeting. Tumori 2013, 99:637-649.
23. King C.R. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models. Brachytherapy 2002, 1(4):219-226.
24. Orton C.G. High-dose-rate brachytherapy may be radiobiologically superior to low-dose rate due to slow repair of late-responding normal tissue cells. Int J Radiat Oncol Biol Phys 2001, 49(1 (Jan 1)):183-189.
25. Heemsbergen W.D., Al-Mamgani A., Slot A., Dielwart M.F.H., Lebesque J.V. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 2014, 110(1 (Jan)):104-109.
26. Hennequin C., Rivera S., Quero L., Latorzeff I. Prostate cancer: doses and volumes of radiotherapy. Cancer Radioth 2010, 14(6-7 (Oct)):474-478.
27. Beckendorf V., Guerif S., Le Prisé E., Cosset J-M., Bougnoux A., Chauvet B., et al. 70Gy vs. 80Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011, 80(4 (Jul 15)):1056-1063.
28. Zaorsky N.G., Den R.B., Doyle L.A., Dicker A.P., Hurwitz M.D. Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer. Expert Rev Med Devices 2013, 10(6 (Nov)):751-763.
29. Demanes D.J., Brandt D., Schour L., Hill D.R. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Am J Clin Oncol 2009, 32(4 (Aug)):342-347.
30. Sathya J.R., Davis I.R., Julian J.A., Guo Q., Daya D., Dayes I.S., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005, 23(6 (Feb 20)):1192-1199.
31. Khor R., Duchesne G., Tai K-H., Foroudi F., Chander S., Van Dyk S., et al. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs. external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys 2013, 85(3 (Mar 1)):679-685.
32. Galalae R.M., Martinez A., Mate T., Mitchell C., Edmundson G., Nuernberg N., et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy [HDR-BT] boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58(4 (Mar 15)):1048-1055.
33. Aström L., Pedersen D., Mercke C., Holmäng S., Johansson K.A. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol 2005, 74(2 (Feb)):157-161.
34. Mate T.P., Gottesman J.E., Hatton J., Gribble M., Van Hollebeke L. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys 1998, 41(3 (Jun 1)):525-533.
35. Dinges S., Deger S., Koswig S., Boehmer D., Schnorr D., Wiegel T., et al. High-dose rate interstitial with external beam irradiation for localized prostate cancer--results of a prospective trial. Radiother Oncol 1998, 48(2 (Aug)):197-202.
36. Hiratsuka J., Jo Y., Yoshida K., Nagase N., Fujisawa M., Imajo Y. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 59(3 (Jul 1)):684-690.
37. Hsu I-C., Bae K., Shinohara K., Pouliot J., Purdy J., Ibbott G., et al. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys 2010, 78(3 (Nov 1)):751-758.
38. Demanes D.J., Rodriguez R.R., Schour L., Brandt D., Altieri G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 2005, 61(5 (Apr 1)):1306-1316.
39. Hoskin P.J., Rojas A.M., Bownes P.J., Lowe G.J., Ostler P.J., Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012, 103(2 (May)):217-222.
40. Mohammed N., Kestin L., Ghilezan M., Krauss D., Vicini F., Brabbins D., et al. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82(1 (Jan 1)):204-212.
41. Grills I.S., Martinez A.A., Hollander M., Huang R., Goldman K., Chen P.Y., et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004, 171(3 (Mar)):1098-1104.
42. Demanes D.J., Martinez A.A., Ghilezan M., Hill D.R., Schour L., Brandt D., et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011, 81(5 (Dec 1)):1286-1292.
43. Zamboglou N., Tselis N., Baltas D., Buhleier T., Martin T., Milickovic N., et al. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys 2013, 85(3 (Mar 1)):672-678.
44. Rogers C.L., Alder S.C., Rogers R.L., Hopkins S.A., Platt M.L., Childs L.C., et al. High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol 2012, 187(1 (Jan)):109-116.
45. Hoskin P., Rojas A., Lowe G., Bryant L., Ostler P., Hughes R., et al. High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys 2012, 82(4 (Mar 15)):1376-1384.
46. Martinez A.A., Demanes J., Vargas C., Schour L., Ghilezan M., Gustafson G.S. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 2010, 33(5 (Oct)):481-488.
47. Ghadjar P., Keller T., Rentsch C.A., Isaak B., Behrensmeier F., Stroux A., et al. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy 2009, 8(1 (Mar)):45-51.
48. Barkati M., Williams S.G., Foroudi F., Tai K.H., Chander S., van Dyk S., et al. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial. Int J Radiat Oncol Biol Phys 2012, 82(5 (Apr 1)):1889-1896.
49. Komiya A., Fujiuchi Y., Ito T., Morii A., Yasuda K., Watanabe A., et al. Early quality of life outcomes in patients with prostate cancer managed by high-dose-rate brachytherapy as monotherapy. Int J Urol 2013, 20(2 (Feb)):185-192.
50. Prada P.J., Jimenez I., González-Suárez H., Fernández J., Cuervo-Arango C., Mendez L. High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results. Brachytherapy 2012, 11(2 (Apr)):105-110.
51. Yoshioka Y., Konishi K., Suzuki O., Nakai Y., Isohashi F., Seo Y., et al. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: a dose reduction trial. Radiother Oncol 2014, 110(1 (Jan)):114-119.
52. Ghilezan M1, Martinez A., Gustason G., Krauss D., Antonucci J.V., Chen P., et al. High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data. Int J Radiat Oncol Biol Phys 2012, 83(3 (Jul 1)):927-932.
53. Tharp M1, Hardacre M., Bennett R., Jones W.T., Stuhldreher D., Vaught J. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy 2008, 7(3 (Jul-Sep)):231-236.
54. Jo Y., Fujii T., Hara R., Yokoyama T., Miyaji Y., Yoden E., et al. Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy-preliminary results. BJU Int 2012, 109(6 (Mar)):835-839.
55. Lee B., Shinohara K., Weinberg V., Gottschalk A.R., Pouliot J., Roach M., et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2007, 67(4 (Mar 15)):1106-1112.
56. Chen C.P., Weinberg V., Shinohara K., Roach M., Nash M., Gottschalk A., et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 2013, 86(2 (Jun 1)):324-329.
57. Yamada Y., Kollmeier M.A., Pei X., Kan C.C., Cohen G.N., Donat S.M., Cox B.W. Zelefsky MJ.A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy 2014, 13(2 (Mar-Apr)):111-116.
58. http://www.clinicaltrials.gov/ct2/results?term=HDR+prostate. [Accessed online on 26.05.14].